Stanley Druckenmiller Bets on Rhythm Pharmaceuticals for Obesity Treatment

Billionaire investor Stanley Druckenmiller is reportedly betting on Rhythm Pharmaceuticals, believing the company can treat a specific form of obesity that Eli Lilly and Novo Nordisk cannot. This highlights a new investment focus in the pharmaceutical sector.